OCS
Oculis Holding AG
There isn't enough reported data to score OCS yet.
OCS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
OCS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OCS PE Valuation
OCS has no meaningful PE right now: it lost money over the past year.
OCS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect OCS's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OCS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.69 | +$1.14 |
| Q1 2026 | -$2.08 | +$0.77 |
| Q4 2025 | -$2.31 | +$0.24 |
| Q3 2025 | -$2.64 | -$0.51 |
| Q2 2025 | -$2.83 | -$0.70 |
| Q1 2025 | -$2.85 | -$0.88 |
| Q4 2024 | -$2.55 | +$0.57 |
| Q3 2024 | -$2.13 | +$0.92 |
OCS is still losing money, but less than at its worst: $1.69 per share over the past year, against $3.12 at its worst in late 2023.
OCS Quarterly Revenue
OCS's revenue has slid since its 2025 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -8352% | N/A |
| Q2 2025 | -7957% | N/A |
| Q1 2022 | -2901% | N/A |
OCS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$24.4M | -$3.5M |
| Q1 2026 | -$18.7M | +$5.4M |
| Q4 2025 | -$20.1M | -$7.6M |
| Q3 2025 | -$16.3M | -$3.6M |
| Q2 2025 | -$20.9M | -$4.6M |
| Q1 2025 | -$24.2M | -$7.6M |
| Q4 2024 | -$12.5M | +$3.1M |
| Q3 2024 | -$12.7M | +$1.7M |
OCS has burned cash in almost every quarter: −$80M over the past year, against −$70M the year before.
OCS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +2.4M shares |
| 1 year | +17% | +9M shares |
| 3 years | +83% | +27.7M shares |
OCS has 61M diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OCS hasn't bought back shares in the past year.
OCS Net Leverage
OCS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OCS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.8 | Oversold |
| Stochastic | 12.7 | Oversold |
OCS's weekly RSI is 30 (oversold) and its Stochastic is 13 (oversold).
OCS PE vs Healthcare Sector
OCS has no meaningful PE right now: it lost money over the past year.
OCS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.10 | 7.4% below |
| 20 week MA | $10.6 | 29% below |
| 50 week MA | $18.7 | 60% below |
| 100 week MA | $18.8 | 60% below |
| 200 week MA | $15.3 | 51% below |
OCS is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
OCS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.69 | $9.70 | +0.1% |
| 2022 | $9.70 | $10.1 | +4% |
| 2023 | $10.1 | $11.2 | +11% |
| 2024 | $11.2 | $17.0 | +51% |
| 2025 | $17.0 | $20.5 | +21% |
| 2026 YTD | $20.5 | $7.50 | -63% |
OCS has finished every year since 2021 higher, and it's down 63% so far in 2026.